7 results about "Rosiglitazone" patented technology

The invention discloses a natural anti-diabetic medicine and a preparation method and application thereof, and the preparation method of the natural anti-diabetic medicine is specifically implemented according to the following steps: step 1, carrying out cold soaking extraction by using 75% industrial ethanol, and respectively extracting by using petroleum ether and ethyl acetate to prepare a notopterygium root extract; 2, separating and purifying the notopterygium root extract obtained in the step 1 by utilizing silica gel column chromatography in combination with high performance liquid chromatography (HPLC) to obtain a single-component compound; the compound is identified as astragalin through nuclear magnetic spectrum and mass spectrum; the natural anti-diabetic drug prepared by the invention can effectively inhibit the increase of the weight, food intake and water intake of diabetic gene mice, and the effect of the natural anti-diabetic drug is superior to that of a first-line drug rosiglitazone for diabetes; the invention can provide a new method for research and development of preparation and application of novel natural anti-diabetic drugs, and also provides a reliable scientific basis for deep development and utilization of the folk drug notopterygium root in China.

The present invention relates to novel Poly(D-glucosamine) co-crystals of Saroglitazar. Specifically, the present invention provides co-crystal of Saroglitazar of formula (I) and Chitosan, process for the preparation of said co-crystal, use thereof and pharmaceutical compositions comprising the same.

The invention relates to the technical field of biological culture, and particularly discloses a culture medium for improving synthesis of unsaturated fatty acid in cell culture fat, which is used for solving the problem that the content of unsaturated fatty acid in the culture fat is not satisfactory. The differentiation culture medium comprises the following components: a basic culture medium, a specific porcine adipose-derived mesenchymal stem cell differentiation induction factor and an unsaturated fatty acid additive. Wherein the specific induction factors comprise but are not limited to factors such as insulin, dexamethasone, indometacin, 3-isobutyl-1-methylxanthine, rosiglitazone and the like. The unsaturated fatty acid additive comprises alpha-linolenic acid, and by adding the substances into the culture medium, the differentiation efficiency of the porcine adipose-derived mesenchymal stem cells and the directional synthesis of the unsaturated fatty acid in the cells can be improved. According to the improved differential culture medium, cell differentiation and unsaturated fatty acid synthesis are effectively promoted by optimizing components and proportions, and the improved differential culture medium has an important application prospect.

The invention belongs to the field of biotechnology and medical technology, and particularly relates to application of a PPAR gamma agonist in preparation of a medicine for preventing, relieving or treating preeclampsia. Experiments find that placenta lipid metabolism abnormality of preeclampsia patients is closely related to PPAR gamma-mediated lipid synthesis increase and metabolic regulation imbalance in an anoxic environment, which shows as trophoblast invasion and migration dysfunction, while the PPAR gamma agonist rosiglitazone can relieve trophoblast dysfunction caused by hypoxia. The PPARgamma antagonist T0070907 can aggravate trophoblast dysfunction caused by hypoxia, and the PPARgamma agonist can be used for preparing the medicine for preventing, relieving or treating preeclampsia, so that preeclampsia treatment is realized, and the life quality and the survival rate of patients are further improved.

The invention discloses an induced differentiation method of sebaceous gland cells, which comprises the following specific steps: adding epidermal stem cells into an induction culture medium, and carrying out induced culture for 5-7 days to obtain the sebaceous gland cells, wherein the adopted induction culture medium is not added with insulin and specifically comprises the following components: 50% of a keratinocyte culture medium, 50% of a sebaceous gland cell culture medium, 1% of antibiotics, 20-40 ng / mL of EGF, 10-40 ng / mL of KGF and 5-20 ng / mL of rosiglitazone. Growth factors EGF and KGF and rosiglitazone are simultaneously added into the induction culture medium, insulin is completely not added, normal division and proliferation of cells are guaranteed, and sebaceous gland cells which are good in growth state and high in differentiation degree are obtained in a short culture period; compared with SZ95, the expression quantities of various sebaceous gland cell markers are similar.

The application discloses a dual-unit fluorescent sensor array for detecting oral anti-diabetic drugs and application thereof, and relates to a supramolecular fluorescent sensor array which comprises a PAL@Q[8] sensing unit and a bpep-Am@Q[8] sensing unit, wherein the PAL@Q[8] sensing unit is composed of palmatine and Q[8], and the bpep-Am@Q[8] sensing unit is composed of a derivative of 1,4-bis[2-(4-pyridyl)vinyl]benzene and Q[8]. The dual-unit fluorescent sensor array can be used for qualitative detection and quantitative detection of metformin, phenformin, buformin hydrochloride, rosiglitazone and sitagliptin in serum or urine, and the method provides a simple and reliable analysis tool for rapid screening of oral hypoglycemic drugs, clinical blood drug concentration monitoring and identification of hypoglycemia causes, so as to realize on-site rapid visual analysis of oral hypoglycemic drugs.